NCT05610956View on ClinicalTrials.gov

Evaluate the Possible Efficacy and Safety of Empagliflozin in Patient With Ulcerative Colitis

EARLY_PHASE1RecruitingINTERVENTIONAL
Enrollment

60

Participants

Timeline

Start Date

January 1, 2023

Primary Completion Date

December 1, 2025

Study Completion Date

December 1, 2026

Conditions
Ulcerative Colitis
Interventions
DRUG

Empagliflozin

Patients will receive empagliflozin (0.4 - 0.5mg/kg/day) orally (maximum dose 25mg per day)and conventional treatment (corticosteroids +immune suppressive + aminosalicylic acid)for 4 months.

DRUG

conventional treatment

conventional treatment (corticosteroids +immune suppressive + aminosalicylic acid)for 4 months

Trial Locations (1)

Unknown

RECRUITING

Gastroenterology and Endoscopy Unit, Internal Medicine Department, Tanta University Hospital., Tanta

All Listed Sponsors
lead

Tanta University

OTHER